Laboratory Guideline Policy - CAM 235HB

Policy
To be considered for reimbursement, all outpatient laboratory claims should be submitted in accordance with: 

  • AMA CPT and HCPCS coding and ICD-10 diagnosis coding guidelines.
  • Other laboratory and pathology coding guidelines.
  • All applicable regulatory guidelines.

This policy outlines additional requirements beyond the guidelines listed above that are required for reimbursement. Note that these guidelines are reviewed and updated periodically.

Technical, Professional, and Global services (-TC, -26 modifiers)

  • Before using the -26 or -TC modifiers, verify that these modifiers are allowable with the procedure code.
  • Do not append these modifiers to the procedure code when performing the global service.

Tests Performed by a Reference Laboratory

  • When performed by a party other than the treating physician, reporting physician, or other qualified health care professional, the laboratory procedure must be identified by adding modifier -90 to the claim line.
  • Only independent clinical laboratories may append modifier -90 to indicate that the service was referred to an outside laboratory.

Repeat Testing

  • While treating a patient, it may be necessary to repeat the same laboratory test on the same day to obtain subsequent (multiple) test results. Under these circumstances, the laboratory test performed can be identified by its usual procedure number and the addition of modifier -91. 
  • When a normal, one-time, reportable result is all that is required, modifier -91 may not be used if tests are rerun to confirm initial results, due to testing problems with specimens or equipment, or for any other reason. 
  • When other code(s) describe a series of test results (e.g., glucose tolerance tests, evocative/suppression testing), modifier -91 may not be used. 

Clinical Laboratory Improvement Amendments (CLIA) Waived Testing

  • Laboratory tests which are CLIA-waived must have the QW modifier appended to the procedure code.

In accordance with S611b of OBRA of 1989, a referring lab can bill for tests performed by a reference lab only if it meets one of the following exceptions:

  • The referring laboratory is in or is part of a rural hospital.
  • The referring lab and the reference lab are 'subsidiary related.' That is:
    • The referring lab is a wholly owned subsidiary of the reference lab
    • The referring lab wholly owns the reference lab
    • Both the referring lab and reference lab are wholly owned subsidiaries of the same entity.

Genetic Counseling Considerations
Reimbursement of genetic counseling is outside the scope of Avalon policies. However, reimbursement of some genetic testing may be dependent on genetic counseling having been performed: any genetic counseling provided will be considered during review of a health plan laboratory policy where genetic counseling is a required component. Genetic counseling documentation consists of written documentation of the counseling elements provided to the member. 

General expectations that should be documented with genetic counseling include explanation of the following: the testing process, what the tests can and cannot do, and how well the tests work. Furthermore, discussion should include what different results mean to the tested individual, including discussing how knowing the test results may affect the individual’s emotions and mental health, as well as how knowing the results may affect the individual’s family. Additionally, diagnostic and treatment options based on results should be discussed. Ideally, when a multigenerational family history is available, this history should be documented and summarized.

Non-Reimbursable CPT/HCPCS Codes
Some procedure codes will not be reimbursed due to their expiration or replacement with more appropriate codes.

  • AMA drug assay codes 80320 to 80377 are not accepted and will not be reimbursed. Refer to policy T2015, Opioids Testing in Pain Management and Substance Abuse, for guidelines for submitting G0480 to G0483.
  • Unlisted codes (81479, 81599, 84999) will not be accepted if a specific Tier 1, Tier 2, GSP, MAAA, or Proprietary Laboratory Analyses (PLA) code exists.
  • PLA codes will not be reimbursed unless a laboratory policy specifically covers the PLA code.

Panel Reimbursement
Genes can be assayed serially or in parallel. Parallel sequencing is when all of the requested genes are assayed on the same date of service with no consideration for the results of another gene assayed during the process. When two or more genes are assayed in parallel using next generation sequencing, then those two or more genes are considered part of the same panel (consistent with NCCI manual Chapter 10, Section F, number 8). Reimbursement for genetic panel testing is as follows:

  • If a procedure code is available for the multi-gene panel test, then this code is to be utilized (i.e., 81442 Noonan spectrum disorders genomic sequence analysis panel).
  • Multi-gene panels must contain the genes specified in the AMA CPT coding description.
  • If there is not a specific next generation sequencing (NGS) procedure code that represents the requested test, a maximum of ONE unit of 81479 [unlisted molecular pathology procedure] may be billed.
  • ALL gene tests in the panel must be listed on the request and rationale for the clinical utility for the gene test must come from the ordering provider.
  • If incorrect codes are submitted to represent panel testing, ALL codes submitted will be denied as not medically necessary due to incorrect coding process.
  • Unless specifically addressed within a policy, concurrent ordering of multi-gene panel tests for a specific condition is strictly prohibited; only one multi-gene panel test may be ordered at a time for a specific condition.
  • Repeat multi-gene panel testing is not allowed unless all of the following are true:  
    1. The individual met all necessary criteria to receive genetic panel testing; 
    2. The individual doesn’t have a previously identified mutation that is causative for the disorder being evaluated; 
    3. The panel being requested contains one or more genes that were previously untested.  

Edit Types
Outpatient lab claims are consistently evaluated for reimbursement against several standard edit types using administrative information (e.g., claim information, historical claims). The specific edits are described below.

Additional Tests on the Date of Service
The presence or absence of additional tests on a single date of service (DOS) may trigger a reimbursement denial for a claim line. 

The exclusivity edit is based upon:

Thus, a denial based upon this edit is one that is based upon evaluation of universal, objective criteria related to how the test is being billed, not an assessment of a patient’s condition to determine whether both codes were appropriate.

Incorrect Diagnosis Code
Select diagnosis and procedure code combinations are permitted or precluded depending on the nature of the policy. 

The edit functions to identify those tests that are never appropriate unless the physician has first concluded that the patient presents with the indicated diagnosis. Although the edit is contingent upon the diagnosis of the individual patient, it is not conducting any clinical evaluation of whether the condition, in fact, exists. Rather, the inherent nature of the test (only being indicated for patients with the condition or contraindicated for the condition) and the question of whether the prerequisite condition is present are the conditions for reimbursement.

Incorrect Patient Age
This edit addresses medical policies with coverage criteria, CPT/HCPCS codes, and diagnosis codes that not are reimbursable based on the patient’s age on the DOS. 
For example, testing on newborns must be associated with a member who is 28 days of age or younger. 

Incorrect Place of Service 
This edit is invoked when the Place of Service is identified as inappropriate with the laboratory test/service performed submitted on the claim. 

Once-per-Lifetime Tests
This edit limits the frequency of applicable laboratory services/procedure codes to once in the patient’s lifetime. 

Certain laboratory services should only be performed once in a patient’s lifetime as outlined in medical policy. If a once-per-lifetime test is submitted for reimbursement more than once, the subsequent submissions will not be reimbursed.

Unit Threshold Met (Daily and Historical)
These edits are invoked when the number of units billed for the procedure on a single DOS or over a period of time exceed an allowed reimbursement quantity without considering any aspect of an individual’s specific condition. Maximum units of service are determined by one or more of the following: 

If a procedure code that is assigned a maximum unit value is reported with a greater unit count, the claim line will be reimbursed only for the number of units up to but not exceeding the allowed maximum.

References

Coding Section

Code 

Number

Description

CPT

0220U 

Oncology (breast cancer), image analysis with artificial intelligence assessment of 12 histologic and immunohistochemical features, reported as a recurrence score

 

0256U

Trimethylamine/trimethylamine N-oxide (TMA/TMAO) profile, liquid chromatography tandem mass spectrometry (LC-MS/MS), urine, with algorithmic analysis and interpretive report

 

0310U 

Pediatrics (vasculitis, Kawasaki disease [KD]), analysis of 3 biomarkers (NTproBNP, C-reactive protein, and T-uptake), plasma, algorithm reported as a risk score for KD

 

0450U 

Oncology (multiple myeloma), liquid chromatography with tandem mass spectrometry (LC-MS/MS), monoclonal paraprotein sequencing analysis, serum, results reported as baseline presence or absence of detectable clonotypic peptides

 

0451U 

Oncology (multiple myeloma), LC-MS/MS, peptide ion quantification, serum, results compared with baseline to determine monoclonal paraprotein abundance

 

0457U 

Perfluoroalkyl substances (PFAS) (eg, perfluorooctanoic acid, perfluorooctane sulfonic acid), 9 PFAS compounds by LC-MS/MS, plasma or serum, quantitative

 

0458U 

Oncology (breast cancer), S100A8 and S100A9, by enzyme-linked immunosorbent assay (ELISA), tear fluid with age, algorithm reported as a risk score

 

0472U 

Carbonic anhydrase VI (CA VI), parotid specific/secretory protein (PSP) and salivary protein (SP1) IgG, IgM, and IgA antibodies, enzyme-linked immunosorbent assay (ELISA), semiqualitative, blood, reported as predictive evidence of early Sjögren’s syndrome

 

0482U 

Obstetrics (preeclampsia), biochemical assay of soluble fms-like tyrosine kinase 1 (sFlt-1) and placental growth factor (PlGF), serum, ratio reported for sFlt-1/PlGF, with risk of progression for preeclampsia with severe features within 2 weeks

 

0483U 

Infectious disease (Neisseria gonorrhoeae), sensitivity, ciprofloxacin resistance (gyrA S91F point mutation), oral, rectal, or vaginal swab, algorithm reported as probability of fluoroquinolone resistance

 

0484U 

Infectious disease (Mycoplasma genitalium), macrolide sensitivity (23S rRNA point mutation), oral, rectal, or vaginal swab, algorithm reported as probability of macrolide resistance

 

0486U

Oncology (pan-solid tumor), next-generation sequencing analysis of tumor methylation markers present in cell-free circulating tumor DNA, algorithm reported as quantitative measurement of methylation as a correlate of tumor fraction

 

0510U 

Oncology (pancreatic cancer), augmentative algorithmic analysis of 16 genes from previously sequenced RNA wholetranscriptome data, reported as probability of predicted molecular subtype

 

0511U 

Oncology (solid tumor), tumor cell culture in 3D microenvironment, 36 or more drug panel, reported as tumor-response prediction for each drug

 

0522U 

Carbonic anhydrase VI, parotid specific/secretory protein and salivary protein 1 (SP1), IgG, IgM, and IgA antibodies

 

0524U 

Obstetrics (preeclampsia), sFlt-1/PlGF ratio, immunoassay, utilizing serum or plasma, reported as a value (This code will be effective on 01/01/2025).

 

0526U 

Nephrology (renal transplant), quantification of CXCL10 chemokines, flow cytometry, urine, reported as pg/mL creatinine baseline and monitoring over time (This code will be effective on 01/01/2025).

 

0527U 

Herpes simplex virus (HSV) types 1 and 2 and Varicella zoster virus (VZV), amplified probe technique, each pathogen reported as detected or not detected (This code will be effective on 01/01/2025).

 

0535U 

Perfluoroalkyl substances (PFAS) (eg, perfluorooctanoic acid, perfluorooctane sulfonic acid), by liquid chromatography with tandem mass spectrometry (LCMS/MS), plasma or serum, quantitative

 

0537U 

Oncology (colorectal cancer), analysis of cell-free DNA for epigenomic patterns, nextgeneration sequencing, >2500 differentially methylated regions (DMRs), plasma, algorithm reported as positive or negative

 

0542U 

Nephrology (renal transplant), urine, nuclear magnetic resonance (NMR) spectroscopy measurement of 84 urinary metabolites, combined with patient data, quantification of BK virus (human polyomavirus 1) using real-time PCR and serum creatinine, algorithm reported as a probability score for allograft injury status

 

0545U 

Acetylcholine receptor (AChR), antibody identification by immunofluorescence, using live cells, reported as positive or negative

 

0546U 

Low-density lipoprotein receptor-related protein 4 (LRP4), antibody identification by immunofluorescence, using live cells, reported as positive or negative

 

0573U 

Oncology (pancreas), 3 biomarkers (glucose, carcinoembryonic antigen, and gastricsin), pancreatic cyst lesion fluid, algorithm reported as categorical mucinous or non-mucinous

 

0614U (effective 04/01/2026)

Inborn error of metabolism (primary mitochondrial disease), mitochondrial analysis of 4 enzyme complexes by stained blue native polyacrylamide gel electrophoresis (PAGE), frozen tissue (muscle, liver, heart, cultured skin fibroblasts), diagnostic qualitative result

 

0618U (effective 04/01/2026)

Psychiatry (bipolar disorder), DNA methylation analysis of more than 10,000 sites, whole blood, algorithm reported as positive or negative risk

 

0619U (effective 04/01/2026)

Pulmonary (chronic obstructive pulmonary disease [COPD]), DNA methylation analysis of more than 18,000 sites, whole blood, algorithm reported as positive or negative risk

 

0622U (effective 04/01/2026)

Psychiatry (major depressive disorder), DNA methylation analysis of more than 20,000 sites, whole blood, algorithm reported as positive or negative risk

 

0623U (effective 04/01/2026)

Autoimmune (multiple sclerosis), DNA methylation analysis of more than 5,000 sites, whole blood, algorithm reported as positive or negative risk

 

0624U (effective 04/01/2026)

Hepatology (nonalcoholic steatohepatitis [NASH]), DNA methylation analysis of 5,000 sites, whole blood, algorithm reported as positive or negative risk

 

0625U (effective 04/01/2026)

Endocrinology (osteoporosis), DNA methylation analysis of more than 5,000 sites, whole blood, algorithm reported as positive or negative risk

 

0626U (effective 04/01/2026)

Neurology (Parkinson disease), DNA methylation analysis of more than 20,000 sites, whole blood, algorithm reported as positive or negative risk

 

0627U (effective 04/01/2026)

Psychiatry (schizophrenia), DNA methylation analysis of more than 15,000 sites, whole blood, algorithm reported as positive or negative risk

 

0629U (effective 04/01/2026)

Infectious disease (tuberculosis), DNA, analysis of 1 target by PCR with clustered regularly interspaced short palindromic repeat (CRISPR)-based probe detection, plasma or serum, qualitative report as detected or not detected


History From 2024 Forward     

03/01/2026 Interim review. Adding PLA codes 0256U, 0614U, 0618U, 0619U, 0622U, 0623U, 0624U, 0625U, 0626U, 0627U, and 0629U effective 04/01/2026. No other changes made. 
01/01/2026
Annual review, updating repeat multi-gene panel section. 
09/01/2025 Annual review, no change to policy intent. 
06/01/2025 Added/updated CPT codes 0220U, 0522U, 0573U effective 07/01/2025.
03/01/2025 Updating CPT coding. Added codes 0310U, 0535U, 0537U, 0542U, 0545U and 0546U. These codes will be effective on 04/01/2025. No other changes made.
11/22/2024
Updated CPT coding. Added codes 0522U, 0524U, 0526U, 0527U. These codes will be effective 01/01/2025. No other changes made
08/27/2024 Interim review. Added PLA codes 0078U, 0482U, 0483U, 0484U, 0486U, 0510U and 0511U to coding section. 
05/03/2024 Annual review moved to January 2025. No other changes. 
01/01/2024 New Policy.
Complementary Content
${loading}